Human Leukocyte Antigen (HLA) Testing Market is expected to reach US$ 1,155.65 Million by 2028

Reagents and Consumables Segment to Hold Larger Share of Human Leukocyte Antigen (HLA) Testing Market During 2022–2028

According to our new research study on “Human Leukocyte Antigen (HLA) Testing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product and Service, Technology, and End User,” the human leukocyte antigen (HLA) testing market is expected to grow from US$ 697.74 million in 2021 to US$ 1,155.65 million by 2028; it is estimated to grow at a CAGR of 7.5% during 2022–2028. The market growth is attributed to the increasing plasma donation and organ transplantation procedures, and the expanding range of applications of HLA testing.

North America held a significant share of the human leukocyte antigen (HLA) testing market in 2021. The growth of the market in countries such as the US and Canada is driven by the increasing demand for organ transplantation, growing technological advancements in human leukocyte antigen (HLA) testing, and a rising number of infectious diseases.

Increasing Number of Plasma Donation and Organ Transplantation Procedures Fuels Human Leukocyte Antigen (HLA) Testing Market Growth:

Human leukocyte antigens (HLAs) are the specialized proteins present on all cell surfaces of the human body, except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues. The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice worldwide. According to data published in Global Observatory on Donation and Transplantation (GODT), in 2020, 129,681 organ transplants were recorded in total. Of these, 31.7% were living kidney transplants and 20.40% were living liver transplants.

Furthermore, the OPTN has used out-of-box strategies to improve organ transplantation. These innovative strategies include the optimized use of organs obtained from deceased patients [e.g., donation after cardiac death (DCD) or brain-dead donors], reducing discards of organs, promoting living donation, and improving the rate of potential organ donation authorization. Thus, the growing demand for organ transplantation leads to the requirement of a more substantial number of HLA testing kits and consumables, which drives the growth of the HLA testing market.

Impact of COVID-19 Pandemic on Human Leukocyte Antigen (HLA) Testing Market:

With the increasing number of infected patients in North American countries, several research institutes and leading organizations put efforts into developing efficient methods for COVID-19 detection. Many health authorities directed their focus on pandemic-related care and avoided human contact due to growing transmission. Postponing elective surgeries, suspending outpatient clinics, and triaging employees involved in urgent care led to further strain on healthcare resources. As per revised COVID-19 guidelines for pediatric orthopedic surgeons, healthcare providers had to shift their focus on urgent care and triaging cases, thus postponing elective surgeries and clinic appointments, along with transitioning to virtual care when appropriate. For instance, an issue published in the British Journal of Surgery, in May 2020, predicted a powerful impact on orthopedic procedures, with the cancellation of 6.3 million operations worldwide.

Thermo Fisher Scientific, Inc.; CareDx; Qiagen; Illumina Inc.; Bio-Rad Laboratories, Inc; TBG Diagnostics Limited; F.Hoffmann-La Roche Ltd; Takara Bio, Inc; Luminex Corporation; Omixon Inc; The Sequencing Center; Protrans; Histogenetics LLC; CD Genomics; Quintara Biosciences; CeGat GmbH; and Creative Biolabs Inc. are among the leading companies operating in human leukocyte antigen (HLA) testing market.

Human Leukocyte Antigen (HLA) Testing Market, by Region, 2022 (%)

---

Human Leukocyte Antigen Testing Market Global Report 2021, 28

Download Free Sample

---

Human Leukocyte Antigen (HLA) Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Services (Reagents & Consumables, Instruments, and Software & Services), Technology [Molecular Assay Technologies (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays, and Others) and Non-Molecular Assay Technologies], and End User (Independent Reference Laboratories, Hospitals and Transplant Centers, and Others), and Geography

Based on product and services, the human leukocyte antigen (HLA) testing market is segmented into reagents and consumables, instruments, and software and services. The market, by technology, is segmented into molecular assay technologies and non-molecular assay technologies. Based on end user, the human leukocyte antigen (HLA) testing market is segmented into independent reference laboratories, hospitals and transplant centers, and others. Based on geography, the market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East and Africa), and South & Central America (Brazil, Argentina, and the Rest of South and Central America).